Axovant Sciences (AXON): Allergan Acquisition of Chase a Positive - Baird

November 23, 2016 6:36 AM EST
Get Alerts AXON Hot Sheet
Price: $13.77 +2.61%

Rating Summary:
    8 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 30 | New: 42
Trade AXON Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Axovant Sciences (NYSE: AXON) after Allergan (NYSE: AGN) announced the acquisition of Chase Pharmaceuticals, a privately held company focusing on development of fixed-dose combinations in Alzheimer's disease, for $125M upfront.

This deal is a direct and clear comp to the recent deal Axovant did with Qaam Pharmaceuticals. As most investors do not attribute value to the Qaam deal, the sizeable economics (upfront ~10% of Axovant market cap) in the Allergan/Chase deal should reflect positively on AXON share price.

No change to the price target of $29.

For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.

Shares of Axovant Sciences closed at $13.45 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Rumors

Related Entities

Robert W Baird, Definitive Agreement

Add Your Comment